Skip to main content

Lexicon Collaborates with Takeda on Hypertension Drug Discovery

NEW YORK, July 27 (GenomeWeb News) - Lexicon Genetics today announced it will collaborate with Takeda to develop new drugs for the treatment of high blood pressure.

 

Under the terms of the agreement, Takeda will have exclusive access to all drug targets that control blood pressure from Lexicon's Genome5000 program. Takeda will be responsible for screening, medicinal chemistry, preclinical and clinical development, and commercialization of drugs directed against Lexicon's targets, the company said.

 

Lexicon will receive an upfront payment of $12 million from Takeda for the initial, three-year term of the agreement. Takeda will have the option of extending the discovery portion of the alliance for an additional two years in exchange for further committed funding, Lexicon said. Lexicon will also earn royalties on worldwide sales of drugs commercialized by Takeda.

 

In the Genome5000 program, Lexicon is using gene knockout technology to discover the function of 5,000 of the most pharmaceutically important genes in the human genome, the company said.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.